The results showed that CCRT combined with IGABT had poor short-term efficacy in LACC patients with lymph node metastasis before treatment (HR = 6.290, 95% CI: 2.211-17.897, p = 0.001), whereas HGB levels (OR = 0.993, 95% CI: 0.963-1.024, p = 0.640), histology (adenocarcinoma vs. squamous cell carcinoma: OR = 4.372, 95% CI: 0.948-20.162, p = 0.059), and tumor stage (Stage IIIB vs Stage IIB: OR = 2.559, 95% CI: 0.893-7.335, p = 0.080) were not significantly associated with short-term efficacy (Figure 1B). The gene discussed is CYGB; the disease is metastatic malignant neoplasm in the lymph nodes.